Nasdaq
$20.25▼ 0.73%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.47BShares out 3.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 1d agoAfter-hours26.10.24 05:058-K/AKey event#●●●#●●●
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, and this filing provides the required historical financial statements and pro forma financial information. Kashiv faced substantial doubt regarding its ability to continue as a going concern as of year-end 2025, and the transaction was funded through the issuance of 28.9 million shares of common stock and $530 million in additional debt.…more
$20.25-0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21After-hours26.09.22 05:334Ownership
Amneal Pharmaceuticals, Inc.
J. Kevin Buchi, an executive at Amneal Pharmaceuticals, reported a change in beneficial ownership of securities effective September 17, 2026. This filing serves as a standard disclosure regarding insider stock holdings.…more
$20.25-0.73%vs prev closeView filingShare - 9.14After-hours26.09.15 05:104Ownership
Amneal Pharmaceuticals, Inc.
Director J. Kevin Buchi of Amneal Pharmaceuticals reported a change in beneficial ownership of company securities on September 11, 2026. This filing formalizes the insider transaction via Form 4.…more
$20.25-0.73%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8Pre-market26.10.08 21:00#●●●#●●●
Amneal Pharmaceuticals to Report Q3 2026 Results on November 3
Amneal Pharmaceuticals announced it will release its financial results for the third quarter of 2026 before the market opens on November 3. The company will also host a conference call to discuss the quarterly performance.…more
$20.25-0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.18After-hours26.09.19 05:01
●●●●●●●● ●●●●● ●●●●●●
Amneal Pharmaceuticals has launched its FDA-approved lanreotide injection, expanding its complex injectables portfolio. The product targets a significant market segment with nearly $1 billion in annual sales, supporting the company's long-term growth.…more
$20.25-0.73%vs prev close - 9.3After-hours26.09.04 05:52
●●●●●●●● ●●●●● ●●●●●●
Amneal Pharmaceuticals has filed a prospectus for the potential sale of up to 28.9 million shares of its Class A common stock by existing shareholders. This secondary offering may lead to concerns regarding potential share dilution.…more
$20.25-0.73%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report